Evidence map›Paper›PMID 38869318›Full record

ArticleACS applied materials & interfaces2024

Surface-Bioengineered Extracellular Vesicles Seeking Molecular Biotargets in Lung Cancer Cells.

Agata Kowalczyk, Damian Dziubak, Artur Kasprzak, Kamil Sobczak, Monika Ruzycka-Ayoush, Magdalena Bamburowicz-Klimkowska, Sławomir Sęk, Ivan Rios-Mondragon, Teresa Żołek, Elise Runden-Pran and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Agata KowalczykFaculty of Chemistry, University of Warsaw, Pasteura Str. 1, Warsaw PL-02-093, Poland.ORCID 0000-0002-1911-8311
Damian DziubakFaculty of Chemistry, University of Warsaw, Pasteura Str. 1, Warsaw PL-02-093, Poland.
Artur KasprzakFaculty of Chemistry, Warsaw University of Technology, Noakowskiego Str. 3, Warsaw 00-664, Poland.ORCID 0000-0002-4895-1038
Kamil SobczakFaculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Żwirki i Wigury 101 Street, Warsaw PL-02-089, Poland.
Monika Ruzycka-AyoushDepartment of Toxicology and Food Science, Faculty of Pharmacy, Medical University of Warsaw, Banacha Str. 1, Warsaw PL-02-097, Poland.ORCID 0000-0002-2838-6625
Magdalena Bamburowicz-KlimkowskaDepartment of Toxicology and Food Science, Faculty of Pharmacy, Medical University of Warsaw, Banacha Str. 1, Warsaw PL-02-097, Poland.
Sławomir SękFaculty of Chemistry, University of Warsaw, Pasteura Str. 1, Warsaw PL-02-093, Poland.ORCID 0000-0002-7741-6448
Ivan Rios-MondragonBiomaterials - Department for Clinical Dentistry, University of Bergen, Årstadveien 19, Bergen 5009, Norway.
Teresa ŻołekDepartment of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha Str. 1, Warsaw PL-02-097, Poland.
Elise Runden-PranHealth Effects Laboratory, Department of Environmental Chemistry, Norwegian Institute for Air Research, Kjeller 2007, Norway.
Sergey ShaposhnikovNorgenotech AS, Gaustadalleen Str. 21, Oslo 0349, Norway.
Mihaela Roxana CimpanBiomaterials - Department for Clinical Dentistry, University of Bergen, Årstadveien 19, Bergen 5009, Norway.
Maria DusinskaHealth Effects Laboratory, Department of Environmental Chemistry, Norwegian Institute for Air Research, Kjeller 2007, Norway.
Ireneusz P GrudzinskiDepartment of Toxicology and Food Science, Faculty of Pharmacy, Medical University of Warsaw, Banacha Str. 1, Warsaw PL-02-097, Poland.
Anna M NowickaFaculty of Chemistry, University of Warsaw, Pasteura Str. 1, Warsaw PL-02-093, Poland.ORCID 0000-0002-5872-6010

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Personalized medicine is a new approach to modern oncology. Here, to facilitate the application of extracellular vesicles (EVs) derived from lung cancer cells as potent advanced therapy medicinal products in lung cancer, the EV membrane was functionalized with a specific ligand for targeting purposes. In this role, the most effective heptapeptide in binding to lung cancer cells (PTHTRWA) was used. The functionalization process of EV surface was performed through the C- or N-terminal end of the heptapeptide. To prove the activity of the EVs functionalized with PTHTRWA, both a model of lipid membrane mimicking normal and cancerous cell membranes as well as human adenocarcinomic alveolar basal epithelial cells (A549) and human normal bronchial epithelial cells (BEAS-2B) have been exposed to these bioconstructs. Magnetic resonance imaging (MRI) showed that the as-bioengineered PTHTRWA-EVs loaded with superparamagnetic iron oxide nanoparticle (SPIO) cargos reach the growing tumor when dosed intravenously in NUDE Balb/c mice bearing A549 cancer. Molecular dynamics (MD) in silico studies elucidated a high affinity of the synthesized peptide to the α5β1 integrin. Preclinical safety assays did not evidence any cytotoxic or genotoxic effects of the PTHTRWA-bioengineered EVs.

Indexed as

Extracellular VesiclesLung NeoplasmsMice, Inbred BALB CMice, NudeA549 CellsAnimalsHumansMagnetic Iron Oxide NanoparticlesMiceextracellular vesicle bioengineeringlung cancer cellsmodel lipid membraneNUDE micepreclinical safety

Identifiers

PMID38869318
PMCPMC11212023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.